Regeneron Pharmaceuticals (REGN) Return on Capital Employed (2010 - 2026)

Regeneron Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 10.19% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 105.0% year-over-year to 10.19%; the TTM figure through Mar 2026 stood at 10.19% (down 105.0% YoY), while the FY2025 annual figure was 10.28%, down 239.0% from the prior year.
• Return on Capital Employed was 10.19% for Q1 2026 at Regeneron Pharmaceuticals, up from 9.94% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 39.73% in Q1 2022 to a low of 9.94% in Q4 2025.
• Historically, Return on Capital Employed has averaged 16.26% across 5 years, with a median of 12.78% in 2024.
• Biggest YoY gain for Return on Capital Employed was 1174 bps in 2022; the steepest drop was 2466 bps in 2022.
• A 5-year view of Return on Capital Employed shows it stood at 18.73% in 2022, then retreated by 26 bps to 13.86% in 2023, then dropped by 14 bps to 11.86% in 2024, then dropped by 16 bps to 9.94% in 2025, then advanced by 3 bps to 10.19% in 2026.
• The last three Return on Capital Employed figures came in at 10.19% (Q1 2026), 9.94% (Q4 2025), and 10.61% (Q3 2025), per Business Quant data.